Scarica l'app Stockscreener
13.47
1.68%
-0.23
Precedente Chiudi:
$13.70
Aprire:
$13.59
Volume 24 ore:
6,091
Relative Volume:
0.09
Capitalizzazione di mercato:
$346.75M
Reddito:
$26.00M
Utile/perdita netta:
$-219.71M
Rapporto P/E:
-0.2705
EPS:
-49.8
Flusso di cassa netto:
$-51.37M
1 W Prestazione:
+10.59%
1M Prestazione:
+26.12%
6M Prestazione:
-29.95%
1 anno Prestazione:
-21.59%
Intervallo 1D:
$13.26
$13.81
Intervallo di 1 settimana:
$12.56
$14.56
Portata 52W:
$8.46
$26.50
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
Nome
Cartesian Therapeutics Inc
Settore
Industria
Telefono
301-348-8698
Indirizzo
7495 NEW HORIZON WAY, FREDERICK
Confronta RNAC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
13.36 | 345.97M | 26.00M | -219.71M | -51.37M | -49.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.44 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.22 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.63 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.75 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
305.08 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-09 | Iniziato | Wedbush | Outperform |
| 2024-12-19 | Iniziato | BTIG Research | Buy |
| 2024-08-06 | Iniziato | TD Cowen | Buy |
| 2024-07-02 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-06-04 | Iniziato | Oppenheimer | Outperform |
| 2024-05-24 | Iniziato | Mizuho | Buy |
| 2024-04-23 | Reiterato | H.C. Wainwright | Buy |
| 2024-04-23 | Iniziato | Leerink Partners | Outperform |
| 2023-08-18 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2022-06-14 | Reiterato | Needham | Buy |
| 2022-06-06 | Iniziato | SVB Leerink | Outperform |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-01-26 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-10-01 | Downgrade | Mizuho | Buy → Neutral |
| 2020-10-01 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-06-12 | Downgrade | Stifel | Buy → Hold |
| 2020-04-28 | Iniziato | H.C. Wainwright | Buy |
| 2020-01-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-01-21 | Iniziato | William Blair | Outperform |
| 2018-06-27 | Iniziato | Janney | Buy |
| 2017-03-30 | Reiterato | UBS | Buy |
Mostra tutto
Cartesian Therapeutics Inc Borsa (RNAC) Ultime notizie
How to use a screener to detect Cartesian Therapeutics Inc. breakoutsPortfolio Booster Strategy with Trend Confidence - Newser
How Cartesian Therapeutics Inc. stock performs during market volatilityOversold Reversal Picks with Buy Zone - Newser
What makes Cartesian Therapeutics Inc. stock price move sharplyFree Weekly Hot Picks With Buy Confidence - Newser
Why Cartesian Therapeutics Inc. stock attracts strong analyst attentionFree Capital Preserving Trade Plan Templates - Newser
How strong is Cartesian Therapeutics Inc. company’s balance sheetSmart Portfolio Ideas For Fast Growth - jammulinksnews.com
Published on: 2025-07-28 21:34:06 - beatles.ru
Cartesian Therapeutics Inc.’s Price Action Aligns with Quant SignalsLow Risk Equity Screener With Results Shared - metal.it
Technical signs of recovery in Cartesian Therapeutics Inc.Short-Term Swing Opportunity Summary Sheet - Newser
Price action breakdown for Cartesian Therapeutics Inc.Buy and Hold Strategy for Capital Safety - Newser
How does Cartesian Therapeutics Inc. generate profit in a changing economySuperior portfolio returns - jammulinksnews.com
How to integrate Cartesian Therapeutics Inc. into portfolio analysis tools Swing Trade Picks with High Potential - Newser
What are Cartesian Therapeutics Inc. company’s key revenue driversExceptional market positioning - jammulinksnews.com
Is Cartesian Therapeutics Inc. stock overvalued or undervaluedAchieve consistent profits with proven methods - jammulinksnews.com
What is the risk reward ratio of investing in Cartesian Therapeutics Inc. stockInvest confidently with data-driven strategies - jammulinksnews.com
New Product Launches: Will They Boost Cartesian Therapeutics Inc. Stock in 2025Free Stock Market Real-Time Monitoring - Newser
How Interest Rate Changes Impact Cartesian Therapeutics Inc. Stock PerformanceControlled Risk High Reward Plan - Newser
What analysts say about Cartesian Therapeutics Inc. stockBreakout portfolio performance - jammulinksnews.com
Cartesian Therapeutics, Inc. (RNAC) Moves 9.9% Higher: Will This Strength Last? - MSN
When is the best time to buy Cartesian Therapeutics Inc. stockSuperior investment outcomes - jammulinksnews.com
What drives Cartesian Therapeutics Inc. stock priceOutstanding trading profits - PrintWeekIndia
Is Cartesian Therapeutics Inc. stock a good hedge against inflationSuperior risk-adjusted returns - jammulinksnews.com
Is Cartesian Therapeutics Inc. a good long term investmentHigh-profit stock alerts - Autocar Professional
AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate - Benzinga
Cartesian Therapeutics Inc. Stock Analysis and ForecastFree Daily Trading Room Entry - Autocar Professional
Chronic Refractory Gout Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Amgen, Cartesian Therapeutics, Swedish Orphan Biovitrum, Arthrosi Therapeutics, TaiwanJ Pharma - Barchart.com
Multiple Myeloma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics - Menafn.com
Cartesian Therapeutics Inc Azioni (RNAC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cartesian Therapeutics Inc Azioni (RNAC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| English Emily | Chief Operations Officer |
Apr 15 '25 |
Option Exercise |
3.30 |
7,500 |
24,750 |
47,726 |
| SPRINGER TIMOTHY A | Director |
Apr 10 '25 |
Buy |
10.47 |
48,595 |
508,751 |
620,175 |
| SPRINGER TIMOTHY A | Director |
Apr 09 '25 |
Buy |
9.43 |
41,782 |
393,947 |
571,580 |
| SPRINGER TIMOTHY A | Director |
Apr 11 '25 |
Buy |
10.77 |
36,338 |
391,455 |
656,513 |
| SPRINGER TIMOTHY A | Director |
Apr 10 '25 |
Buy |
10.47 |
8,575 |
89,773 |
8,637,273 |
| SPRINGER TIMOTHY A | Director |
Apr 09 '25 |
Buy |
9.43 |
7,373 |
69,517 |
8,628,698 |
| SPRINGER TIMOTHY A | Director |
Apr 11 '25 |
Buy |
10.77 |
6,412 |
69,074 |
8,643,685 |
| SPRINGER TIMOTHY A | Director |
Mar 20 '25 |
Buy |
15.59 |
54,889 |
855,593 |
8,621,325 |
| SPRINGER TIMOTHY A | Director |
Mar 19 '25 |
Buy |
14.97 |
20,234 |
302,962 |
8,566,436 |
| SPRINGER TIMOTHY A | Director |
Mar 18 '25 |
Buy |
14.42 |
14,740 |
212,599 |
8,546,202 |
1.47%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):